Tamoxifen: the drug that came in from the cold

AUTOR(ES)

Hughes-Davies, L

FONTE

Nature Publishing Group

RESUMO

Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

Documentos Relacionados

• Hepatic Elastography in the Assessment of Heart Failure: Where We Came from and Where We Are Going
• Drug points: Cold urticaria triggered by griseofulvin
• The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice
• Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
• Isolation of a beta-tubulin gene from Fusarium moniliforme that confers cold-sensitive benomyl resistance.